AbbVie’s purchase of Allergan expands patent scope
The acquisition is a play by the Illinois-based pharma giant to mitigate the impact of losing exclusivity of Humira, but it also gives it strength in underrepresented areas of its portfolio
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.